{"id":"NCT00811720","sponsor":"H. Lundbeck A/S","briefTitle":"Efficacy of Nalmefene in Patients With Alcohol Dependence","officialTitle":"Nalmefene Efficacy Study I: Randomised, Double-blind, Placebo-controlled, Parallel-group, Efficacy Study of 20 mg Nalmefene, As-needed Use, in Patients With Alcohol Dependence","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2010-10","completion":"2010-11","firstPosted":"2008-12-19","resultsPosted":"2013-07-09","lastUpdate":"2013-07-09"},"enrollment":598,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Alcohol Dependence"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Nalmefene","otherNames":["Selincroâ„¢"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Nalmefene","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate the efficacy, safety and tolerability of nalmefene in the treatment of alcohol dependence.","primaryOutcome":{"measure":"Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)","timeFrame":"Baseline and Month 6","effectByArm":[{"arm":"Placebo","deltaMin":-8.91,"sd":0.56},{"arm":"Nalmefene 18.06 mg","deltaMin":-11.24,"sd":0.6}],"pValues":[{"comp":"OG000 vs OG001","p":"0.002"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":39,"countries":["Austria","Finland","Germany","Sweden"]},"refs":{"pmids":["23237314","25832297","25227627","23873853"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":296},"commonTop":["Dizziness","Nausea","Fatigue","Nasopharyngitis","Headache"]}}